ArticleRheumatology international2017
Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout.
Article in Rheumatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Reno-protective effects of xanthine oxidase inhibitors in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis.Journal of nephrology · 2025Pooled it
- Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials.African health sciences · 2021Pooled it
- Elevated uric acid level and metabolic syndrome in Non-Hispanic Black American adults.Journal of diabetes and metabolic disorders · 2025Article
- Serum Uric Acid Is Associated with Insulin Resistance in Non-Diabetic Subjects.Journal of clinical medicine · 2025Article
- Febuxostat Improves Postprandial Glucose Regulation and Insulin Sensitivity in Hyperuricemic Individuals with Prediabetes or Newly Diagnosed Type 2 Diabetes: A Prospective Cohort Study.Drug design, development and therapy · 2025Article
- Uncovering the Potential Mechanisms and Effects of Hyperuricemia and its Associated Diseases on Male Reproduction.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- Machine Learning Insights Into Uric Acid Elevation With Thiazide Therapy Commencement and Intensification.Cureus · 2023Article
- Contributing Factors of Diabetes Mellitus among Patients with Gout (Results of the Long-Term Prospective Study).Doklady. Biochemistry and biophysics · 2023Article
- Correlation Analysis between Uric Acid and Metabolic Syndrome in the Chinese Elderly Population: A Cross-Sectional Study.International journal of endocrinology · 2023Article
- The Management of Diabetes with Hyperuricemia: Can We Hit Two Birds with One Stone?Journal of inflammation research · 2023Review
- Do thrifty genes exist? Revisiting uricase.Obesity (Silver Spring, Md.) · 2022Review
- Hyperuricemia prevalence and its association with metabolic disorders: a multicenter retrospective real-world study in China.Annals of translational medicine · 2021Article
- Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.Frontiers in endocrinology · 2021Article
- Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age.International journal of molecular sciences · 2020Review
- Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to investigate the effects of febuxostat on IR and the expression of high-sensitivity C-reactive protein (hs-CRP) in patients with primary gout. Forty-two cases of primary gout patients without uric acid-lowering therapy were included in this study. After a physical examination, 20 age- and sex-matched patients were included as normal controls. The levels of fasting insulin (INS), fasting blood glucose (FBG), and hs-CRP were determined. IR was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Gout patients had higher levels of UA, INS, HOMA-IR, and hs-CRP than normal controls (P < 0.05). After 4-, 12-, and 24-week febuxostat treatments, UA and hs-CRP concentrations were significantly lower than baseline (P < 0.05). INS and HOM-IR decreased slightly after a 4-week treatment with febuxostat but declined significantly after 12 and 24 weeks of treatment. Importantly, hs-CRP values positively correlated with those of HOMA-IR (r = 0.353, P = 0.018) and INS (r = 0.426, P = 0.034). Our findings confirm that IR exists in gout patients and implicate that febuxostat can effectively control the level of serum UA and increase insulin sensitivity in primary gout patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.